AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test
Comprehensive Introduction to AML ETO Gene Rearrangement Testing
The AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test represents a cutting-edge molecular diagnostic approach for detecting specific chromosomal abnormalities in acute myeloid leukemia (AML). This sophisticated test identifies the translocation between chromosomes 8 and 21, specifically involving the AML1 (RUNX1) gene on chromosome 21 and the ETO (RUNX1T1) gene on chromosome 8. This genetic rearrangement creates the AML1-ETO fusion gene, which plays a critical role in the development and progression of certain subtypes of acute myeloid leukemia.
As one of the most common cytogenetic abnormalities in AML, the t(8;21) translocation occurs in approximately 5-12% of all AML cases and is particularly prevalent in the M2 subtype according to the French-American-British (FAB) classification system. The detection of this specific genetic marker is essential for accurate diagnosis, prognosis assessment, and treatment planning in leukemia management.
What the Test Measures and Detects
The AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test utilizes advanced Real-Time Polymerase Chain Reaction (PCR) technology to specifically identify the presence of the AML1-ETO fusion gene. This molecular diagnostic approach offers several key detection capabilities:
- Specific Fusion Gene Detection: Precisely identifies the AML1-ETO fusion transcript resulting from the t(8;21) translocation
- High Sensitivity Monitoring: Capable of detecting minimal residual disease (MRD) with exceptional sensitivity
- Qualitative Assessment: Provides definitive presence or absence results for the genetic abnormality
- Treatment Response Evaluation: Enables monitoring of therapeutic effectiveness over time
The test’s qualitative nature ensures reliable detection of the specific genetic rearrangement, making it an invaluable tool for both initial diagnosis and ongoing patient management.
Who Should Consider This Test
The AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test is recommended for individuals presenting with specific clinical indications and symptoms suggestive of acute myeloid leukemia:
Clinical Indications:
- Patients with suspected or newly diagnosed acute myeloid leukemia
- Individuals exhibiting unexplained cytopenias (low blood counts)
- Patients with persistent fatigue, weakness, or unexplained bruising
- Those experiencing recurrent infections or fever of unknown origin
- Individuals with abnormal bone marrow findings
- Patients requiring treatment response monitoring
- Individuals undergoing minimal residual disease assessment
Symptom Presentation:
- Unexplained fatigue and general weakness
- Frequent infections and fever
- Easy bruising or bleeding tendencies
- Pale skin or shortness of breath
- Bone or joint pain
- Unintended weight loss
- Enlarged lymph nodes or spleen
Significant Benefits of AML ETO Testing
Choosing the AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test provides numerous advantages for both patients and healthcare providers:
- Accurate Diagnosis: Enables precise identification of specific AML subtypes for targeted treatment approaches
- Prognostic Information: Provides valuable insights into disease prognosis and expected treatment outcomes
- Treatment Guidance: Helps oncologists develop personalized treatment strategies based on genetic markers
- Disease Monitoring: Facilitates ongoing assessment of treatment response and disease progression
- Early Detection: Allows for prompt intervention and management of relapsing disease
- Therapeutic Decision Support: Informs decisions regarding chemotherapy intensity and duration
- Minimal Residual Disease Assessment: Provides sensitive monitoring for residual leukemia cells
Understanding Your Test Results
Interpreting the results of the AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test requires professional medical expertise, but here is general guidance:
Positive Result:
- Indicates the presence of the AML1-ETO fusion gene
- Confirms diagnosis of AML with t(8;21) translocation
- Suggests favorable prognosis with appropriate treatment
- May indicate the need for specific therapeutic approaches
- Provides baseline for future monitoring and MRD assessment
Negative Result:
- Absence of detectable AML1-ETO fusion gene
- Suggests alternative genetic abnormalities may be present
- May indicate different AML subtypes requiring alternative diagnostic approaches
- Could suggest complete molecular remission in follow-up testing
All results should be discussed with your oncologist or hematologist for proper interpretation and treatment planning. The qualitative nature of this test provides clear presence/absence information, making it particularly valuable for diagnostic confirmation and monitoring purposes.
Test Pricing and Availability
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $150 |
| Regular Price | $226 |
Test Specifications:
- Turnaround Time: Sample collection Monday/Thursday by 11 AM; Results available Wednesday/Saturday
- Sample Type: 3 mL (2 mL minimum) whole blood or bone marrow from 1 Lavender Top (EDTA) tube
- Shipping Instructions: Ship refrigerated. DO NOT FREEZE
- Preparation: No special preparation required
- Methodology: Real-Time PCR
- Specialty: Oncologist
- Department: Molecular Diagnostics
- Disease Focus: Leukemia
Nationwide Testing Availability
GGC DNA maintains comprehensive testing facilities across the United States, ensuring accessible molecular diagnostic services for patients nationwide. Our network includes specialized testing centers in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many other cities.
Each facility is equipped with state-of-the-art molecular diagnostic equipment and staffed by experienced laboratory professionals specializing in hematological malignancies. Our standardized protocols ensure consistent, reliable results regardless of testing location.
Take Action for Your Health
Early detection and accurate diagnosis are crucial for effective leukemia management. The AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test provides the precise genetic information needed for optimal treatment planning and monitoring.
Ready to schedule your test? Contact our dedicated patient services team today to book your appointment or discuss testing options with our genetic counselors. Call or WhatsApp us at +1(267) 388-9828 for immediate assistance and personalized guidance.
Take the first step toward comprehensive leukemia management with GGC DNA’s advanced molecular diagnostics. Our team is committed to providing accurate, timely results to support your healthcare journey.
